Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Thomas TrayPrincipal Accounting Officer | IncyteINCY | Open-market sale10b5-1 plan | 06/04 | 06/08 | 2,639 sh | $100.00 | $263,900 | −11.1% |
Thomas TrayPrincipal Accounting Officer | IncyteINCY | Open-market sale10b5-1 plan | 05/26 | 05/28 | 2,051 sh | $97.35 | $199,664.85 | −8.8% |
Paul J. ClancyDirector | IncyteINCY | Open-market sale10b5-1 plan | 05/19 | 05/21 | 15,000 sh | $94.93 | $1,423,950 | −38.7% |
Pablo J. CagnoniPresident, Global Head of R&D | IncyteINCY | Open-market sale10b5-1 plan | 04/17 | 04/21 | 18,667 sh | $96.50 | $1,801,365.5 | −6.6% |
Pablo J. CagnoniPresident, R&D | IncyteINCY | Open-market sale10b5-1 plan | 03/17 | 03/19 | 18,667 sh | $94.24 | $1,759,178.08 | −7.4% |
Pablo J. CagnoniPresident, R&D | IncyteINCY | Open-market sale10b5-1 plan | 02/19 | 02/23 | 18,668 sh | $100.91 | $1,883,787.88 | −7.4% |
Mohamed Khairie IssaEVP, Head of US Oncology | IncyteINCY | Open-market sale10b5-1 plan | 01/07 | 01/08 | 10,856 sh | $109.07 | $1,184,063.92 | −14.1% |
Steven H. SteinEVP & Chief Medical Officer | IncyteINCY | Open-market sale10b5-1 plan | 01/05 | 01/07 | 15,634 sh | $101.70 | $1,589,977.8 | −31.4% |
IncyteINCY | Open-market sale10b5-1 plan | 25/12/18–25/12/19 | 25/12/22 | 3,374 sh2 trades | $99.69avg. | $336,350 | −12.8% | |
IncyteINCY | Open-market sale10b5-1 plan | 25/12/16–25/12/17 | 25/12/18 | 58,331 sh3 trades | $97.29avg. | $5,675,001.59 | −68.0% | |
IncyteINCY | Open-market sale10b5-1 plan | 25/12/10–25/12/11 | 25/12/12 | 5,808 sh2 trades | $95.55avg. | $554,965.44 | −8.8% | |
IncyteINCY | Open-market sale10b5-1 plan | 25/12/01–25/12/02 | 25/12/03 | 22,664 sh2 trades | $102.56avg. | $2,324,438.19 | −26.4% | |
IncyteINCY | Open-market sale10b5-1 plan | 25/11/21–25/11/24 | 25/11/25 | 769 sh2 trades | $102.78avg. | $79,038 | −3.2% | |
Sheila A. DentonEVP & General Counsel | IncyteINCY | Open-market sale10b5-1 plan | 25/11/17 | 25/11/19 | 278 sh | $104.36 | $29,012.08 | −1.0% |
Herve HoppenotDirector | IncyteINCY | Open-market sale10b5-1 plan | 25/11/10 | 25/11/12 | 187,500 sh | $105.46 | $19,773,750 | −36.3% |
Steven H. SteinEVP & Chief Medical Officer | IncyteINCY | Open-market sale10b5-1 plan | 25/11/05 | 25/11/07 | 5,233 sh | $102.20 | $534,812.6 | −4.8% |
Sheila A. DentonEVP & General Counsel | IncyteINCY | Open-market sale10b5-1 plan | 25/11/04 | 25/11/06 | 598 sh | $101.36 | $60,613.28 | −2.2% |
Lee HeesonEVP, Head of Incyte Intl | IncyteINCY | Open-market sale10b5-1 plan | 25/11/03 | 25/11/05 | 3,074 sh | $94.02 | $289,017.48 | −9.5% |
Sheila A. DentonEVP & General Counsel | IncyteINCY | Open-market sale10b5-1 plan | 25/10/15 | 25/10/17 | 277 sh | $85.13 | $23,581.01 | −1.0% |
IncyteINCY | Open-market sale10b5-1 plan | 25/10/02–25/10/03 | 25/10/06 | 4,100 sh2 trades | $85.85avg. | $351,977.89 | −13.4% |